FGFR3 inhibitor

DRUG CLASS:

FGFR3 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
FGFR2 fusion	Urothelial Cancer	FGFR2 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Cholangiocarcinoma	FGFR2 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Gastric Cancer	FGFR2 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Gastric Cancer	FGFR3 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Solid Tumor	FGFR2 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 mutation	Bladder Cancer	FGFR2 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2	HMPL-453 Sensitive: C2 – Inclusion Criteria HMPL-453 Sensitive : C2
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3
FGFR3-BAIAP2L1 fusion	Urothelial Cancer	FGFR3-BAIAP2L1 fusion	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
ER positive + FGFR3 amplification	HER2 Negative Breast Cancer	ER positive + FGFR3 amplification	HER2 Negative Breast Cancer	palbociclib + erdafitinib Sensitive: C3 – Early Trials palbociclib + erdafitinib Sensitive : C3	palbociclib + erdafitinib Sensitive: C3 – Early Trials palbociclib + erdafitinib Sensitive : C3
ER positive + FGFR1 amplification	HER2 Negative Breast Cancer	ER positive + FGFR1 amplification	HER2 Negative Breast Cancer	palbociclib + erdafitinib Sensitive: C3 – Early Trials palbociclib + erdafitinib Sensitive : C3	palbociclib + erdafitinib Sensitive: C3 – Early Trials palbociclib + erdafitinib Sensitive : C3
FGFR1 fusion	Cholangiocarcinoma	FGFR1 fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 R248C	Urothelial Cancer	FGFR3 R248C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR2-BICC1 fusion	Urothelial Cancer	FGFR2-BICC1 fusion	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 S249C	Urothelial Cancer	FGFR3 S249C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 G370C	Urothelial Cancer	FGFR3 G370C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 Y373C	Urothelial Cancer	FGFR3 Y373C	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR2-CASP7 fusion	Urothelial Cancer	FGFR2-CASP7 fusion	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3-TACC3 fusion	Glioblastoma	FGFR3-TACC3 fusion	Glioblastoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Urothelial Cancer	FGFR fusion	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR2-BICC1 fusion	Endometrial Cancer	FGFR2-BICC1 fusion	Endometrial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR2-OFD1 fusion	Endometrial Cancer	FGFR2-OFD1 fusion	Endometrial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3

FGFR3 inhibitor

FGFR3 inhibitor

Associations(77)

Associations
(77)